TG THERAPEUTICS, INC. Other Nonoperating Income (Expense)
TG THERAPEUTICS, INC. (TGTX) reported Other Nonoperating Income (Expense) of $5.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-08-05
- TG THERAPEUTICS, INC. other nonoperating income (expense) for the quarter ending 2026-06-30 was $5.13M, a 83.75% increase year-over-year.
- TG THERAPEUTICS, INC. other nonoperating income (expense) for the quarter ending 2026-03-31 was $2.39M, a 33.75% decline year-over-year.
- TG THERAPEUTICS, INC. other nonoperating income (expense) for the quarter ending 2025-12-31 was $1.13M, a 55.87% decline year-over-year.
- TG THERAPEUTICS, INC. other nonoperating income (expense) for the quarter ending 2025-09-30 was $3.27M, a 22.47% increase year-over-year.
- TG THERAPEUTICS, INC. other nonoperating income (expense) for fiscal 2025 was $10.79M, a 40.30% increase from fiscal 2024.
- TG THERAPEUTICS, INC. other nonoperating income (expense) for fiscal 2024 was $7.69M, a 52.52% increase from fiscal 2023.
- TG THERAPEUTICS, INC. other nonoperating income (expense) for fiscal 2023 was $5.04M, a 7.43% increase from fiscal 2022.
- TG THERAPEUTICS, INC. other nonoperating income (expense) for fiscal 2022 was $4.70M, a 103.51% increase from fiscal 2021.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 9 month | Other Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.13M 10-Q · filed 2026-08-05 | $7.52M 10-Q · filed 2026-08-05 | $8.65M derived: sum of 3 quarters · filed 2026-08-05 | $11.92M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.39M 10-Q · filed 2026-05-06 | $3.52M derived: sum of 2 quarters · filed 2026-05-06 | $6.78M derived: sum of 3 quarters · filed 2026-05-06 | $9.58M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $4.40M derived: sum of 2 quarters · filed 2026-02-27 | $7.19M derived: sum of 3 quarters · filed 2026-08-05 | $10.79M 10-K · filed 2026-02-27 |
| 2025-09-30 | $3.27M 10-Q · filed 2025-11-05 | $6.06M derived: sum of 2 quarters · filed 2026-08-05 | $9.66M 10-Q · filed 2025-11-05 | $12.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.79M 10-Q · filed 2026-08-05 | $6.40M 10-Q · filed 2026-08-05 | $8.96M derived: sum of 3 quarters · filed 2026-08-05 | $11.63M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $3.60M 10-Q · filed 2026-05-06 | $6.17M derived: sum of 2 quarters · filed 2026-05-06 | $8.83M derived: sum of 3 quarters · filed 2026-05-06 | $10.55M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $5.23M derived: sum of 2 quarters · filed 2026-02-27 | $6.94M derived: sum of 3 quarters · filed 2026-02-27 | $7.69M 10-K · filed 2026-02-27 |
| 2024-09-30 | $2.67M 10-Q · filed 2025-11-05 | $4.38M derived: sum of 2 quarters · filed 2025-11-05 | $5.13M 10-Q · filed 2025-11-05 | $6.15M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $1.71M 10-Q · filed 2025-08-08 | $2.59M 10-Q · filed 2025-08-08 | $3.48M derived: sum of 3 quarters · filed 2026-02-27 | $6.34M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $880.00K 10-Q · filed 2025-05-09 | $1.77M derived: sum of 2 quarters · filed 2026-02-27 | $4.63M derived: sum of 3 quarters · filed 2026-02-27 | $5.32M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $890.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $3.75M derived: sum of 2 quarters · filed 2026-02-27 | $4.44M derived: sum of 3 quarters · filed 2026-02-27 | $5.04M 10-K · filed 2026-02-27 |
| 2023-09-30 | $2.86M 10-Q · filed 2024-11-07 | $3.55M derived: sum of 2 quarters · filed 2024-11-07 | $4.15M 10-Q · filed 2024-11-07 | $6.08M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $691.00K 10-Q · filed 2024-08-09 | $1.29M 10-Q · filed 2024-08-09 | $3.23M derived: sum of 3 quarters · filed 2025-03-03 | $4.02M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $604.00K 10-Q · filed 2024-05-06 | $2.53M derived: sum of 2 quarters · filed 2025-03-03 | $3.33M derived: sum of 3 quarters · filed 2025-03-03 | |
| 2022-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $2.72M derived: sum of 2 quarters · filed 2025-03-03 | $4.70M 10-K · filed 2025-03-03 | |
| 2022-09-30 | $793.00K 10-Q · filed 2023-11-06 | $2.77M 10-Q · filed 2023-11-06 | ||
| 2021-12-31 | $2.31M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |